Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows

by Vandana Singh, Benzinga Editor

May 26, 2021 9:04 AM | 1 min read |

Altimmune Inc ALT has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate.
Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 variant that originated in South Africa.
The neutralizing titer against the B.1.351 variant virus was only 4.4-fold lower than the original Wuhan-like isolate when measured seven weeks after a single intranasal dose of AdCOVID.
Furthermore, in mice that received a booster dose of AdCOVID, the reduction in the neutralizing titer against the variant was only 1.8-fold lower at seven weeks post-vaccination; statistically the same as the neutralization titer against the Wuhan isolate.
Price Action: ALT shares are up 5.2% at $12.41 during the premarket session on the last check Wednesday.

Posted In: Biotech News Health Care Small Cap General Briefs COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.